Paul Baas
Leiden University(NL)Dutch Cancer Society(NL)Leiden University Medical Center(NL)The Netherlands Cancer Institute(NL)Oncode Institute(NL)Dana-Farber Cancer Institute(US)Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital(NL)
Publications by Year
Research Areas
Occupational and environmental lung diseases, Lung Cancer Treatments and Mutations, Pleural and Pulmonary Diseases, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer(2015)8,490 cited
- → Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial(2015)6,477 cited
- → The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer(2016)4,558 cited
- → First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial(2021)1,154 cited
- → Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer(2019)952 cited
- → Photodynamic Therapy in Oncology